Clinical Trials on Raynaud's Phenomenon (Secondary) in Argentina

Total 9 results

Hospital Privado de Comunidad de Mar del Plata

Completed

Functional Residual Capacity Measured by Capnography in Ventilated Patients

Respiratory Physiological Phenomena

Argentina
NeuroHealing Pharmaceuticals Inc.
Michael J. Fox Foundation for Parkinson's Research

Completed

Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients (NH004-2)

Sialorrhea Secondary to Parkinson's Disease

Argentina
Antisoma Research

Unknown

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Korea, Republic of, United States, Spain, United Kingdom, Australia, Austria, Taiwan, Israel, Italy, Belgium, Germany, France, Romania, Estonia, Canada, Ukraine, Ecuador, Hungary, Poland, Chile, Argentina, Czech Republic, Russian Federation
Takeda

Recruiting

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Multiple Myeloma | Secondary Immunodeficiency (SID)

Greece, Spain, Italy, Romania, Argentina, Czechia, France, Germany, Poland, Sweden, Turkey
Amgen

Recruiting

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, United States, India, Singapore, Taiwan, Argentina, Malaysia, Russian Federation, Turkey, Ukraine
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

Geographic Atrophy Secondary to Age-related Macular Degeneration

United States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Stroke | Secondary Prevention

Korea, Republic of, United States, Spain, Canada, Germany, Taiwan, Belgium, Australia, Hong Kong, India, Singapore, Thailand, Greece, Italy, Japan, China, Turkey, Russian Federation, Serbia, Switzerland, Israel, South Africa, Malaysia, Fran... and more
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
Novartis Pharmaceuticals

Completed

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

China, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Japan, Bulgaria, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, Slo... and more

Clinical Trials on Raynaud's Phenomenon (Secondary) in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations